entertainment -WSS

entertainment

author：comprehensive 2025-09-30 22:09:54 - browse：2

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： White House pharmacy plagued with problems, investigation finds

focus

hotspot

knowledge

WSS

New clues to why women have higher risk of autoimmune disorders

Health Care Service Corp to buy Cigna Medicare Advantage plans

Latest bird flu infection made farmworker sicker than earlier cases

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Philips to halt sales of sleep apnea machines in U.S.

Childbirth

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hollywood unions extend contract negotiations for actors

Stigma and the return of syphilis

Continuity nursing helped my family in our darkest PICU moments

Akili, maker of video game for ADHD, to be acquired for 34 million

In age of alternative facts, a scholarly course on calling out crap

Average age of first period drops to 11.9 years, study shows

Novavax promises a turnaround & Lilly roils the obesity market

Vertex non

Bright Health sells Medicare Advantage business to Molina

David Sabatini, ex

focus

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Insmed lung disease drug hits target in key Phase 3 trial

What will save rural psychiatry services? Higher Medicaid payments

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Why Medicare shouldn’t cover every FDA

Venture capital firm's plans to take over Akron hospital face hurdles

hotspot

knowledge

knowledge

leisure time